Imsidolimab is a monoclonal antibody commercialized by AnaptysBio, with a leading Phase III program in Generalized Pustular Psoriasis (GPP). According to Globaldata, it is involved in 10 clinical trials, of which 5 were completed, and 5 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Imsidolimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Imsidolimab is expected to reach an annual total of $22 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Imsidolimab Overview
Imsidolimab (ANB-019) is under development for the treatment of generalized pustular psoriasis (GPP). It is administered through the subcutaneous and intravenous route. The drug candidate acts by targeting the interleukin-36 receptor (IL-36R). It is developed based upon somatic hypermutation (SHM) Platform.
It was under development for the treatment of palmo-plantar pustular psoriasis (PPP), hidradenitis suppurativa, palmoplantar pustulosis (PPP),acne vulgaris, Ichthyosis and EGFRi/MEKi therapy mediated acneiformrash.
AnaptysBio Overview
AnaptysBio (Anaptys) is a clinical-stage biotechnology company. It is focused on advancing immune cell-modulating antibodies for autoimmune and inflammatory diseases. The company’s product candidates include rosnilimab, a PD-1 agonist in trials for rheumatoid arthritis and ulcerative colitis, and ANB032, a BTLA agonist in development for atopic dermatitis. Its preclinical pipeline features ANB033, targeting CD122 to manage inflammation, and ANB101, a BDCA2 modulator to regulate dendritic cells. The company is also advancing cytokine antagonists imsidolimab, targeting IL-36R for generalized pustular psoriasis, and etokimab, an IL-33 antagonist. Anaptys is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$17.2 million for the fiscal year ended December 2023 (FY2023), an increase of 66.8% over FY2022. The operating loss of the company was US$164.4 million in FY2023, compared to an operating loss of US$115.2 million in FY2022. The net loss of the company was US$163.6 million in FY2023, compared to a net loss of US$128.7 million in FY2022.
The company reported revenues of US$11 million for the second quarter ended June 2024, an increase of 52.8% over the previous quarter.
For a complete picture of Imsidolimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
